MOTS-c and Humanin are both encoded by mitochondrial DNA and classified as mitochondria-derived peptides, but they work through different receptors, target different tissues, and have distinct research profiles — understanding both helps clarify which context each one is being studied in.
TelosRX evaluates peptide therapies based on their emerging research evidence. MOTS-c and Humanin represent two of the most studied mitochondria-derived peptides (MDPs), a class that has grown rapidly in longevity and metabolic research over the past decade.
What Are Mitochondria-Derived Peptides?
Mitochondrial DNA (mtDNA) was long thought to encode only 13 proteins — all components of the electron transport chain — along with ribosomal and transfer RNAs. That assumption shifted when researchers discovered small open reading frames (sORFs) within the mitochondrial genome capable of encoding short bioactive peptides.
These mitochondria-derived peptides act as signaling molecules, communicating mitochondrial stress and metabolic status to other cells and tissues. MOTS-c and Humanin are the two most extensively characterized MDPs to date.
MOTS-c vs Humanin: Head-to-Head Comparison
| Feature | MOTS-c | Humanin |
|---|---|---|
| Gene location | 12S rRNA region of mtDNA | 16S rRNA region of mtDNA |
| Peptide length | 16 amino acids | 21 amino acids (HNG: 24 aa) |
| Primary role | Metabolic regulation, exercise response | Cytoprotection, neuroprotection |
| Key receptor/target | AMPK activation; nuclear translocation under stress | gp130/LIFR receptor complex; formyl peptide receptor 2 |
| Primary action | Improves insulin sensitivity; activates one-carbon metabolism | Anti-apoptotic; protects neurons and cardiomyocytes |
| Stability/half-life | Short in vivo; under active investigation | Short; HNG (S14G-Humanin) is a more stable analog |
| Exercise response | Increases with physical activity (skeletal muscle source) | Less directly exercise-responsive |
| Primary research areas | Insulin resistance, metabolic syndrome, aging, obesity | Neurodegeneration (Alzheimer’s), cardiomyocyte protection, age-related decline |
| Regulatory status | Research compound; not FDA-approved | Research compound; not FDA-approved |
MOTS-c: What the Research Shows
MOTS-c was first characterized in 2015 by Lee et al. (Cell Metabolism), who demonstrated that it activates AMPK and regulates one-carbon metabolism in a way that improves insulin sensitivity in mice on a high-fat diet.
Key findings from subsequent research:
- Skeletal muscle source: Unlike Humanin, MOTS-c is primarily produced by skeletal muscle during exercise. Circulating MOTS-c levels rise with physical activity, suggesting it functions as a myokine communicating metabolic status systemically.
- Insulin resistance: Multiple studies in rodent models have shown MOTS-c improves glucose tolerance and insulin sensitivity, particularly in the context of diet-induced obesity.
- Age-related decline: Circulating MOTS-c levels decline with age in both animal models and humans. A 2023 study (PubMed 36799414) found lower MOTS-c levels correlated with worse metabolic parameters in older adults.
- Nuclear translocation: Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus where it acts as a transcriptional regulator — a distinct mechanism beyond classical peptide signaling.
Humanin: What the Research Shows
Humanin was discovered in 2001 from a cDNA library derived from surviving neurons of an Alzheimer’s disease brain — identified because it protected against neuronal death induced by AD-associated genetic mutations.
Key research areas:
- Neuroprotection: Humanin inhibits neuronal apoptosis induced by amyloid-beta (Aβ) and other AD-associated insults. It works through gp130 receptor signaling and by blocking the pro-apoptotic protein BAX.
- Cardiomyocyte protection: Humanin reduces ischemia-reperfusion injury in cardiac models by decreasing apoptosis during oxygen deprivation and re-oxygenation.
- Systemic aging marker: Like MOTS-c, circulating Humanin levels decline with age. A 2023 study (PMC12652385) found lower Humanin in older adults and in those with age-related metabolic and cognitive conditions.
- HNG analog: The S14G-Humanin (HNG) variant is approximately 1,000-fold more potent than native Humanin in neuroprotection assays and has greater in vivo stability, making it the preferred form in most contemporary preclinical studies.
Do MOTS-c and Humanin Interact?
Emerging evidence suggests MOTS-c and Humanin may act synergistically. A 2021 study in Science Advances found that combined supplementation with both MDPs in aged mice produced greater improvements in metabolic parameters and physical function than either peptide alone. The proposed mechanism is complementary: MOTS-c acting primarily on metabolic pathways in skeletal muscle and adipose tissue, while Humanin protects post-mitotic cells (neurons, cardiomyocytes) against apoptosis.
Which Mitochondrial Peptide to Consider
This distinction matters for research framing, not as a clinical recommendation — neither MOTS-c nor Humanin is FDA-approved, and the human evidence base remains largely observational and mechanistic.
In research contexts:
- MOTS-c has attracted more interest in metabolic syndrome, insulin resistance, obesity-related conditions, and exercise physiology
- Humanin has a stronger neurological research focus, particularly in models of neurodegeneration and ischemic injury
If you are exploring peptide therapies through TelosRX’s asynchronous peptide program, your licensed clinician reviews your health history and goals during intake. Compounded peptides are not FDA-approved and are prepared under federal compounding regulations. Use is subject to medical approval by a licensed provider; approval is not guaranteed.
Frequently Asked Questions
Are MOTS-c and Humanin available as supplements?
Some products marketed as MOTS-c or Humanin are sold as oral supplements, but peptides are poorly absorbed orally without specialized delivery. Compounded injectable or subcutaneous formulations are used in research and clinical contexts, and are subject to medical evaluation and regulatory oversight.
Do circulating levels of these peptides predict health outcomes?
Observational associations have been documented — lower MOTS-c and Humanin levels correlate with worse metabolic and cognitive markers in older adults. Whether restoring levels through exogenous administration produces the same benefits is an open research question that clinical trials will need to address.
Which has more human evidence: MOTS-c or Humanin?
Both have primarily preclinical (animal and cell) evidence bases. Human studies are emerging but limited in scale and duration. Neither has completed a large randomized controlled trial demonstrating clinical outcomes in humans.
Can someone take both MOTS-c and Humanin at the same time?
Preclinical data suggest complementary rather than overlapping mechanisms, and combined administration has been studied in animal models. In a clinical context, combination use would be evaluated by a licensed provider based on individual health history and goals.
Are mitochondrial peptides the same as traditional peptides like BPC-157 or TB-500?
No. Traditional therapeutic peptides are encoded by nuclear DNA. MDPs like MOTS-c and Humanin are uniquely encoded by mitochondrial DNA, making them a separate class with distinct signaling roles tied to cellular energy status and stress response.
Start your private evaluation at TelosRX.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.